Exacerbations · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Response rate ‐ treatment failure · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to lower response rate ‐ treatment failure compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ microbiological response · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to higher response rate ‐ microbiological response compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ improvement in sputum purulence (excellent) · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
It is very uncertain whether fluoroquinolones changes response rate ‐ improvement in sputum purulence (excellent) compared with amoxicillin (very low certainty).
1 finding from 1 review
Deaths · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Quality of life · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
Diarrhoea · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes diarrhoea on compared with macrolides (very low certainty).
1 finding from 1 review
Relapse ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with macrolides (very low certainty).
1 finding from 1 review
Diarrhoea · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes diarrhoea on compared with beta‐lactams (very low certainty).
1 finding from 1 review
Relapse · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes relapse ‐ All trials clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
Serious adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes serious adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes adverse events leading to discontinuation of treatment compared with beta‐lactams (very low certainty).
1 finding from 1 review